BARCELONA, Spain, October 21, 2025--(BUSINESS WIRE)--Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical ...
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...
To date, no disease-modifying therapies have been approved for PSP. The PROSPER study is a randomized, double-blind, placebo-controlled trial 3 that has successfully recruited the planned number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results